Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  leukemia
Results 1-25 of 973 for your search:
Start Over
Alisertib in Combination with Cytarabine and Idarubicin in Treating Patients with High-Risk Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-334, NCI-2016-00332, NCT02560025
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: Not specified
Trial IDs: E2993T2, NCI-2009-01080, CDR0000529758, ECOG-E2993T2, NCT00899366
Biomarker Study in Bone Marrow Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 1 to under 31
Trial IDs: AALL10B1, NCI-2011-02848, CDR0000695252, COG-AALL10B1, NCT01295476
Donor Lymphocytes after Combination Chemotherapy in Treating Patients with Acute Myeloid Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and older
Trial IDs: 021208, NCI-2013-02408, CINJ# 021208, FWA00003913, Pro2013002693, NCT02105116
Different Schedules of Decitabine in Treating Older Patients with Previously Untreated Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: 2012-1017, NCI-2013-00463, NCT01786343
18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: 2014-0616, NCI-2015-00525, NCT02390635
Sirolimus and Azacitidine in Treating Patients with High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That Is Relapsed or Refractory or Not Eligible for Intensive Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12D.587, NCI-2013-01004, 2012-50, NCT01869114
Selinexor, Fludarabine Phosphate, and Cytarabine in Treating Younger Patients with Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 24 and under
Trial IDs: SELHEM, NCI-2014-01704, NCT02212561
Laboratory-Treated Donor Cord Blood Cell Transplant in Treating Patients with Relapsed or Refractory Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 1 to 80
Trial IDs: 2010-0658, NCI-2011-03742, NCT01471067
Leuprolide Acetate in Improving Immune Recovery and 18F FLT PET/CT in Predicting Immune Recovery after Donor Bone Marrow Transplant in Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 9 to 55
Trial IDs: 11-C-0136, NCI-2013-01485, 110136, P10780, NCT01338987
Cognitive Behavioral Intervention for Targeted Therapy Fatigue Intervention
Status: Active
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: MCC-18365, NCI-2015-01891, 18365, NCT02592447
Donor T-cells after Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 14 to 75
Trial IDs: IRB12-1191, NCI-2013-00782, NCT01839916
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Donor Umbilical Cord Blood Transplant After Combination Chemotherapy and Total-Body Irradiation in Treating Patients With Hematological Diseases
Status: Not yet active
Phase: No phase specified
Type: Supportive care, Treatment
Age: 0 to 55
Trial IDs: 2013OC013, NCI-2013-02269, MT2013-09C, NCT01962636
Safety Study of Nivolumab by Itself or in Combination With Ipilimumab or in Combination With Lirilumab in Patients With Lymphoma and Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA209-039, NCI-2012-02776, NCT01592370
Conventional and Regulatory T Cells in Treating Patients With Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
T-cell Depleted Stem Cell Boost in Improving Graft Function in Patients Who Have Undergone Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 14-228, NCI-2015-00179, NCT02350777
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH 13H11, CMH SCT 0813, SCT 0813 Haplo, NCT02053545
Selinexor in Treating Younger Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 21 years
Trial IDs: 13-563, NCI-2014-00936, KPT330, NCT02091245
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: IRB00007195, NCI-2012-01084, CA180-392, NCT01620216
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TED10893, NCI-2010-02332, U1111-1116-5472, NCT01084252
Gemtuzumab Ozogamicin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, or Chronic Myelogenous Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 months and over
Trial IDs: CCCWFU# 99213, NCI-2013-00965, NCT01869803
Start Over